Literature DB >> 16966178

Fluconazole resistance mechanisms in Candida krusei: the contribution of efflux-pumps.

J Guinea1, M Sánchez-Somolinos, O Cuevas, T Peláez, E Bouza.   

Abstract

The main resistance mechanism for fluconazole in Candida krusei is the diminished sensitivity of the target enzyme cytochrome P450 sterol 14 alpha-demethylase (CYP51) to inhibition by azole agents. An alternative mechanism of resistance, efflux-pump activity, has been proposed. The aim of our study was to find out the possible contribution of efflux-pumps in conferring resistance to fluconazole in 33 C. krusei isolates from different clinical sources. The activity of efflux-pumps was checked using the inhibitor CCCP (carbonyl cyanide 3-chloro-phenylhydrazone), which decreases the minimum inhibitory concentration (MIC) when resistance is attributed. We established a concentration of 0.5 microg/ml of CCCP. The susceptibility patterns of our isolates for five antifungal drugs (amphotericin B, fluconazole, itraconazole, flucytosine and voriconazole) were determined according to an NCCLS M27-A2 protocol modification (Sensititre Yeast One). We tested all the strains before and after adding CCCP to the RPMI medium. The MIC90s and ranges of the drugs were identical before and after addition of CCCP. The MIC for fluconazole was higher than for the other antifungals. The new triazoles were active and the MICs were lower, although this should be interpreted carefully as the drugs showed different cut-offs. Only one isolate showed a two-fold decrease in MIC to fluconazole when CCCP was added. We did not find any multi-resistant strains. According to our study with C. krusei, CCCP-inhibited efflux-pumps do not play a significant role in resistance to fluconazole.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16966178     DOI: 10.1080/13693780600561544

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  20 in total

Review 1.  Will resistance in fungi emerge on a scale similar to that seen in bacteria?

Authors:  H Hof
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-19       Impact factor: 3.267

2.  Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; M A Pfaller; B Bustamante; E Canton; A Fothergill; J Fuller; G M Gonzalez; C Lass-Flörl; S R Lockhart; E Martin-Mazuelos; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M W Szeszs; G St-Germain; L X Bonfietti; J Guarro; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

3.  In vivo and in vitro acquisition of resistance to voriconazole by Candida krusei.

Authors:  Elisabete Ricardo; Isabel M Miranda; Isabel Faria-Ramos; Raquel M Silva; Acácio Gonçalves Rodrigues; Cidália Pina-Vaz
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

4.  Repurposing of Ribavirin as an Adjunct Therapy against Invasive Candida Strains in an In Vitro Study.

Authors:  Hanane Yousfi; Carole Cassagne; Stéphane Ranque; Jean-Marc Rolain; Fadi Bittar
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

5.  Phytosphingosine-1-phosphate is a signaling molecule involved in miconazole resistance in sessile Candida albicans cells.

Authors:  Davy Vandenbosch; Anna Bink; Gilmer Govaert; Bruno P A Cammue; Hans J Nelis; Karin Thevissen; Tom Coenye
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

6.  In vitro activities of fluconazole and voriconazole against clinical isolates of Candida spp. determined by disk diffusion testing in Turin, Italy.

Authors:  Narcisa Mandras; Vivian Tullio; Valeria Allizond; Daniela Scalas; Giuliana Banche; Janira Roana; Francesca Robbiano; Giacomo Fucale; Aurelio Malabaila; Anna Maria Cuffini; Nicola Carlone
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

7.  Candida parapsilosis Resistance to Fluconazole: Molecular Mechanisms and In Vivo Impact in Infected Galleria mellonella Larvae.

Authors:  Ana Carolina R Souza; Beth Burgwyn Fuchs; Henrique M S Pinhati; Ricardo A Siqueira; Ferry Hagen; Jacques F Meis; Eleftherios Mylonakis; Arnaldo L Colombo
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191

8.  Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.

Authors:  Erwin Lamping; Amrita Ranchod; Kenjirou Nakamura; Joel D A Tyndall; Kyoko Niimi; Ann R Holmes; Masakazu Niimi; Richard D Cannon
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

Review 9.  Mechanisms of Candida Resistance to Antimycotics and Promising Ways to Overcome It: The Role of Probiotics.

Authors:  Konstantin A Demin; Aleksandr G Refeld; Anna A Bogdanova; Evgenya V Prazdnova; Igor V Popov; Olga Yu Kutsevalova; Alexey M Ermakov; Anzhelica B Bren; Dmitry V Rudoy; Vladimir A Chistyakov; Richard Weeks; Michael L Chikindas
Journal:  Probiotics Antimicrob Proteins       Date:  2021-03-18       Impact factor: 4.609

10.  Antifungal and Antibiofilm Activities of Selective Serotonin Reuptake Inhibitors Alone and in Combination with Fluconazole.

Authors:  Yamaç Tekintaş; Aybala Temel; Ayşegül Ateş; Bayrı Eraç; Dilek Yeşim Metin; Süleyha Hilmioğlu Polat; Mine Hoşgör Limoncu
Journal:  Turk J Pharm Sci       Date:  2020-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.